 SAN DIEGO, Jan. 05, 2022 GLOBE NEWSWIRE -- Prometheus Biosciences, Inc. Nasdaq: RXDX, a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST. 